




<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
K6	1	Data Processed Using Dissprof Program (V1.1), Oxybutynin C1, Joint Exhibit 25, November 24, 2003 MYLAN 1014396-1014492	
	2	Skelly, J.P. et al., "In Vitro and In Vivo Testing and Correlation for Oral Controlled/Modified-Release Dosage Forms", <i>Pharmaceutical Research</i> , 1990, 7(9), 975-977, Joint Exhibit 67	
	3	Theeuwes, F. et al., "Osmotic Delivery Systems for the $\beta$ -Adrenoceptor Antagonists Metoprolol and Oxprenolol: Design and Evaluation of Systems for Once-Daily Administration, <i>Br. J. Clin. Pharmac.</i> , 1985, 19, 695-765, Joint Exhibit 81,	
	4	Oxybutynin, ALZA/TDC Meeting, Friday July 15, 1993, Palo Alto, Ca. Defendant's Exhibits DX 00028, DXL-016926 thru DXL-016976	
	5	Ballard, B.E., "Prolonged-Action Pharmaceuticals", Chapter 91, Defendant's Exhibit DX 00403, 1594-1613	
	6	Corrigan, O.I. et al., "Influence of Dissolution Medium Buffer Composition on Ketoprofen Release from ER Products and in Vitro—in Vivo Correlation", <i>International Journal of Pharmaceutics</i> , 2003, 147-154, Defendant's Exhibit DX 00408	
	7	Frick, A. et al., "Biopharmaceutical Characterization of Oral Controlled/Modified-Release Drug Products. In Vitro/in Vivo Correlation of Roxatidine", <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 1998, 46, 313-319, Defendant's Exhibits DX 00411	
	8	Drug Class Review on Urinary Incontinence Drugs", Final Report, February 2003, Oregon Health & Science University, Defendant's Exhibit DX 00431	
	9	Oregon Health Resources Commission, Urinary Incontinence (Update Report) Update #1, March 2004, 12 pages, Defendant's Exhibit DX 00432	
	9B	Ouslander, J.G. et al., "Pharmacokinetics and Clinical Effects of Oxybutynin in Geriatric Patients", <i>The Journal of Urology</i> , 1988, 140, 47-50, Defendant's Exhibit DX 00433	
K6	10	Qiu, Y. et al., "Once-a-Day Controlled-Release Dosage Form of Divalproex Sodium II: Development of a Predictive In Vitro Drug Release Method", <i>Journal of Pharmaceutical Sciences</i> , November 2003, 92(11), 2317-2325, Defendant's Exhibit DX 00437	
EXAMINER		DATE CONSIDERED 4.6.06	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>K6</b>	<b>11</b>	ALZA Communication Exchange, A.C.E. Briefing, "The Making of Ditropan® XL: An Epic Celebrating the Cast of ALZAns who made it Happen, from 1993 to Today", January 20, 1999, DXL-063089 thru DXL-063100, Defendant's Exhibit DX 00448,	
	<b>12</b>	Theeuwes, et al., "Elementary Osmotic Pump for Indomethacin", <i>Journal of Pharmaceutical Sciences</i> , March 1983, 72(3), 253-258, Defendant's Exhibit DX 00450	
	<b>12A</b>	Thuroff, J.W. et al., "Randomized, Double-Blind, multicenter Trial on Treatment of Frequency, Urgency and Incontinence related to Detrusor Hyperactivity: Oxybutynin Versus Propantheline Versus Placebo", <i>The Journal of Urology</i> , April 1991, 145, 813-817, Defendant's Exhibit DX 00453	
	<b>13</b>	Welling, P.G., "In Vitro Methods to Determine Bioavailability: In Vitro-In Vivo Correlations", 223 thru 232, Defendant's Exhibits DX 00462	
	<b>14</b>	Executive Summary, OROS® (Oxybutynin Chloride) CPC-1, October 1997, DXL-031021 thru DXL-063202, Defendant's Exhibit DX 01079	
	<b>15</b>	Stage 0: Product Concept Assessment Form Synopsis, March 2, 1993, DXL- 063198 thru 063202, Defendant's Exhibits DX 01143	
	<b>16</b>	Ditropan Xl and Market Pricing, Defendant's Exhibit DX 01151, JJ-00447 thru JJ-00456	
	<b>17</b>	Harry C. Boghician (Portfolio), 5 pages Defendant's Exhibit DX 1216 A	
	<b>18</b>	In the United States District Court for the Northern District of West Virginia, ALZA Corporation, Plaintiff v. Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc. Defendants, C.A. No.: 1:03CV61, Expert Report of James A. Forstner, April 29, 2004, Defendant's Exhibit DX 01219	
	<b>19</b>	Curriculum Vitae-Gordon L. Amidon, Defendant's Exhibit DX 01226, 93 pages	
	<b>20</b>	Fax Letter from Jeffrey I.D. Lewis to James H. Wallace, Defendant's Exhibit DX 01245, 2 pages	
<b>K6</b>	<b>21</b>	Curriculum Vitae, Stanley Kandzari, M.D. Updated April 1, 2005, Defendant's Exhibit DX 1266 B, 1page	
<b>EXAMINER</b> <b>K6</b>		<b>DATE CONSIDERED</b> 4.6.06	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>KG</b>	<b>22</b>	Experimental Formula Sheet-Sustained Release Oxybutynin Chloride Pellets, MYLAN 1014435, <b>Defendant's Exhibit DX 01403</b>	
	<b>23</b>	Australia Patents Act, "Complete Specification for Sustained Release Pharmaceutical Composition, 55 pages	
	<b>24</b>	Saks, S.R. MD, "Pharmacokinetics of OROS® and Oxybutynin", <i>ALZA Corporation Physician Advisory Board Meeting, October 9-11, 1998, DXL-044580 thru 004591</i> <b>Defendant's Exhibit DX 1501</b>	
	<b>25</b>	Winkler, H.A. et al., "Treatment of Detrusor Instability with Oxybutynin Rectal Suppositories" <i>International Urogynecology Journal</i> , 1998, 9, 100-102, <b>Defendant's Exhibit DX 1503, 3 pages</b>	
	<b>26</b>	Massad, C.A. et al., "The Pharmacokinetics of Intravesical and Oral Oxybutynin Chloride", <i>The Journal of Urology</i> , 1992, 148, 595-597, <b>Defendant's Exhibit DX 1504</b>	
	<b>27</b>	<b>Defendant's Exhibit DX 1507, DXL084950 thru DXL084985</b>	
	<b>28</b>	Projected Ditropan XI Net Trade Sales, <b>Defendant's Exhibit DX 1511, 5 pages</b>	
	<b>29</b>	Quarterly TRX Market Share and TRX Following Launch(Quarterly), <b>Defendant's Exhibits DX 1512,</b>	
<b>KG</b>	<b>30</b>	Gupta, S. PhD., "New Pharmacokinetic Information on Ditropan® XL, <i>Physician Advisory Board Meeting, Medical Education Technologies Job # AZ11-0013,</i> <b>Defendant's Exhibit DX 1515C, DXL 045275 thru 045313</b>	
<b>KG</b>	<b>31</b>	Stage 0: Product Concept Assessment Form Synopsis, March 2, 1993, <b>Defendant's Exhibit DX 1517, DXL 063216 thru 063222</b>	
<b>EXAMINER</b> <b>KG</b>		<b>DATE CONSIDERED</b> 4-6-06	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>K6</b>	<b>32</b>	Final Report C-96-074-02 "Effect of Food on the Pharmacokinetics and Bioavailability of OROS® (oxybutynin chloride) relative to Ditopan®", November 1997, DXL-081963 thru 081999, <b>Defendant's Exhibit DX 1530</b>	
	<b>33</b>	Oxybutynin Chloride, <b>Defendant's Exhibit DX 1540</b> , DXL 050624 ,050505 thru 050516, 9 pages	
	<b>34</b>	Oxybutynin Chloride, <b>Defendant's Exhibit DX 1541</b> , DXL 050625, 1 page	
	<b>35</b>	<b>Defendant's Exhibit DX 1542</b> , 1 page	
	<b>36</b>	<b>Defendant's Exhibit DX 1543</b> , ALZA Expert 00267, 1 page	
	<b>37</b>	Genitourinary Smooth Muscle Relaxants, <i>American Hospital Formulary Service</i> , 1997, <b>Defendant's Exhibit DX 1544</b> , DXL 079384 thru DXL 079387	
	<b>38</b>	Letter from Jeffrey I.D. Lewis to Nicholas A Peppas, Ph.D., <b>Defendant's Exhibits 1546</b> , 5 pages	
	<b>39</b>	In the United States District Court for the Southern District of Florida, Pfizer, Inc. and Alza Corporation, Plaintiffs, v. Andrx Corporation, Andrx Pharmaceuticals, inc., and Andrx Pharmaceuticals, LLC, Defendants, C.A. No.: 01-8636, Amended Complaint, <b>Defendant's Exhibit DX 1548</b> , 17 pages	
	<b>40</b>	Siepmann, J. et al., "HPMC-Matrices for Controlled Drug Delivery: A New Model Combining Diffusion, Swelling, and Dissolution Mechanisms and Predicting the Release Kinetics", <i>Pharmaceutical Research</i> , 1999, 16(11), 1748-1756, <b>Defendant's Exhibit DX 1551</b>	
<b>K6</b>	<b>41</b>	Siepman, J. et al., "A New Model Describing the Swelling and Drug Release Kinetics from Hydroxypropyl Methylcellulose Tablets", <i>Journal of Pharmaceutical Sciences</i> , January 1999, 88(1), 65 thru 72, <b>Defendant's Exhibit DX 1552</b>	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	<b>4-6-06</b>

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>KG</b>	<b>42</b>	Baker, R., "Controlled Release of Biologically Active Agents", 1987, 1-21, <b>Defendant's Exhibit DX 1553</b>	
	<b>43</b>	'355 Claim 1 vs. Baichwal Example 15 Data, 1 page, <b>Defendant's Exhibit 1554</b>	
	<b>44</b>	'355 Claim 1 vs. Baichwal Example 15 vs. Example 1, 1 page, <b>Defendant's Exhibit 1557,</b>	
	<b>45</b>	Fundamentals of Controlled Release and Pharmaceutical Engineering, Spring 1993, <b>Defendant's Exhibit DX 1558</b>	
	<b>46</b>	'355 Claim 1 vs. '355 Example 1 Data, <b>Defendant's Exhibit DX 1559</b> , 1 page	
	<b>47</b>	U.S. Pharmacopeia & National Formulary, <b>Defendant's Exhibit DX 1561</b> , 2232-2240	
	<b>48</b>	Figure 1 of the '355 Patent: Typical Release Curve for 24-Hour Controlled Release Data, <b>Defendant's Exhibit DX 1562, 1563</b> 2 pages	
	<b>49</b>	General Requirements for Tests and Assays, <b>Defendant's Exhibit DX 1566</b> , 1833 thru 1861	
	<b>49A</b>	Moore, K. et al., "Oxybutynin Hydrochloride (3mg) in the Treatment of Women with Idiopathic Detrusor Instability", <i>British Journal of Urology</i> , 1990, 66, 479-485, <b>Defendant's Exhibit DX 1570</b>	
	<b>50</b>	USP Dissolution Calibrator, Non-Disintegrating Type, <b>Defendant's Exhibit DX 1573</b> , 2 pages	
<b>KG</b>	<b>51</b>	Oxybutynin Chloride ER (OXYB-0262) Data, <b>Defendant's Exhibit DX 1580-DX 1586</b> , Mylan 0060307, 1 page	
EXAMINER 		DATE CONSIDERED 4-6-06	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Gulttard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>K6</b>	<b>52</b>	Reviewer Guidance-Validation of Chromatographic Methods, <i>Center for Drug Evaluation and Research (CDER)</i> , November 1994, 1 thru 30, <b>Defendant's Exhibit 1588</b>	
	<b>53</b>	Drug Release Profile Data- <b>Defendant's Exhibit DX 1589</b> , MYLAN 1014490-1014492	
	<b>54</b>	Drug Release Profile Data- <b>Defendant's Exhibit DX 1590</b> , MYLAN 1014485-1014487	
	<b>55</b>	Drug Release Profile Data- <b>Defendant's Exhibit DX 1591</b> , MYLAN 1014477-1014479	
	<b>56</b>	Drug Release Profile Data- <b>Defendant's Exhibit DX 1592</b> , MYLAN 1014480-1014482	
	<b>57</b>	ALZA Corporation-Payments to Virginia Commonwealth University Data- <b>Defendant's Exhibit 1593</b> , DXL 085000-085017	
	<b>58</b>	Mylan 10 mg Product-Apparatus 2(Paddle) with Media Switch Data- <b>Defendant's Exhibit DX 1594-1598</b>	
	<b>59</b>	U.S. Pharmacopeia & National Formulary, <b>Defendant's Exhibit DX 1803</b> , 1128-1129	
	<b>60</b>	Baichwal Teaches the Conventional Wisdom Data- <b>Defendant's Exhibit DX 1804</b> , 1 page	
<b>K6</b>	<b>61</b>	Mylan 5mg Product Data- <b>Defendant's Exhibit DX 1805</b> , 7 pages	
<b>EXAMINER</b> <b>K6</b>		<b>DATE CONSIDERED</b> 4-6-06	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>KG</b>	<b>62</b>	Mylan 10 mg Product Data-Defendant's Exhibit DX 1806, 4 pages	
	<b>63</b>	Concentration Result Data-Defendant's Exhibit DX 1808, 1 page	
	<b>64</b>	U.S. Pharmacopeia- The Official Compendia of Standards, Defendant's Exhibit 1814, 4 pages	
	<b>65</b>	Mylan 10 mg Product, Mylan 5 mg Product Data- Defendant's Exhibit DX 1816-1817	
	<b>66</b>	U.S. Pharmacopeia- The Official Compendia of Standards, Defendant's Exhibit 1818, 6-8, 2160-2165	
	<b>67</b>	Mylan 10 mg Product Data- Defendant's Exhibit DX 1819, 1 page	
	<b>68</b>	U.S. Pharmacopeia- The Official Compendia of Standards, Defendant's Exhibit 1821, 2513-2519	
	<b>69</b>	Copy of CD- Defendant's Exhibit DX 1822	
	<b>70</b>	'355 Claim 1 vs. Examples A and B Data- Defendant's Exhibit 1823, 1 page	
<b>KG</b>	<b>71</b>	Data- Defendant's Exhibit 1825, 1 page	
<b>EXAMINER</b> <b>KG</b>		<b>DATE CONSIDERED</b> <b>4-6-06</b>	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>KG</b>	<b>72</b>	Mylan Tablet Data-Defendant Exhibits 1827 thru 1831	
	<b>73</b>	5 mg Oral Solution Data-Defendant's Exhibit 1832-1833, 46 pages	
	<b>74</b>	Mylan Tablet Data-Defendant's Exhibit 1836, 1 page	
	<b>75</b>	Mylan Tablet Data-Defendant's Exhibit 1900-1901	
	<b>76</b>	Miyamoto, E. et al., "Physico-Chemical Properties of Oxybutynin", <i>Analysts</i> , July 1994, 119, 1489-1492, Defendant's Exhibit 1902, DXL 005871-005874	
	<b>77</b>	State of the Art: Colonic Absorption Studies, Defendant's Exhibit DX 2001, 1 page	
	<b>78</b>	Colonic Absorption Studies and Data-Defendant's Exhibit DX 2002	
	<b>79</b>	Wong, P.S.L. et al., "Osmotically Controlled Tablets", <i>Modified-Release Drug Delivery Technology</i> , 2003, 101-114 Joint Exhibit 109	
	<b>80</b>	ALZA: OROS® Oral Delivery Technology, March 9, 2004, <a href="http://www.alza.com/print/oros">http://www.alza.com/print/oros</a> , Joint Exhibit 111, 2 pages	
<b>KG</b>	<b>81</b>	Patent Information: DITROPAN XL®(oxybutynin chloride) Extended Release Tablet, Joint Exhibit 112, DXL 070943	
<b>EXAMINER</b> <b>KG</b>		<b>DATE CONSIDERED</b> 4-6-06	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>CG</b>	<b>82</b>	Douchamps, J. et al., "The Pharmacokinetics of Oxybutynin in Man", <i>Eur J. Clin Pharmacol</i> , 1988, 35, 515-520, <b>Joint Exhibit 116, 5 pages</b>	
	<b>83</b>	Cystrin® SR, Sustained Release Oxybutynin Hydrochloride, Development Pharmaceuticals, <b>March 9, 1994, PW 000225-PW 000280, Joint Exhibit 130</b>	
	<b>84</b>	Patent Data, DXL 070941-070942, <b>Joint Exhibit 131</b>	
	<b>85</b>	The United States Pharmacopeia Convention, Inc. 1990, 1790-1799, <b>Joint Exhibit 133</b>	
	<b>86</b>	Oxybutynin/Official Monographs, <b>Joint Exhibit 134, 1 page</b>	
	<b>87</b>	The United States Pharmacopeia Convention, Inc., The Official Compendia of Standards, 2002, 2010-2022, <b>Joint Exhibit 135</b>	
	<b>88</b>	<b>Joint Exhibit 137, 1578-1581</b>	
	<b>89</b>	Van Bommel, E.M.G. et al., "Comparison of <i>In Vitro</i> and <i>In Vivo</i> Release Characteristics of Acetaminophen from Gradient Matrix Systems, <i>Biopharmaceutics &amp; Drug Disposition</i> , 1991, 12, 367-373, <b>Joint Exhibit 139</b>	
	<b>90</b>	Oxybutynin Chloride Extended-Release Tablets, 10 MG, Uniformity of Dosage Units (FP-OXYB10-CU-M), 5514-5539, MYLAN 0065620-0065646, <b>Joint Exhibit 232</b>	
<b>KG</b>	<b>91</b>	Preik, M. et al., "Effect of Controlled-Release Delivery on the Pharmacokinetics of Oxybutynin at Different Dosages: Severity-Dependent Treatment of the Overactive Bladder", <i>BJU International</i> , 2004, 821-827, <b>Plaintiff's Exhibit 396</b>	
<b>EXAMINER</b>		<b>KG</b>	<b>DATE CONSIDERED</b> 4/6/06

<b>Form PTO-1449 Modified</b>  <b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
<b>16</b>	<b>92</b>	Patent Data, <b>Plaintiff's Exhibit 40, 43, 53, 54, 58, 59</b> , 1 page each, 6 total pages	
	<b>93</b>	Leesman, G.D. et al., "Simulation of Oral Drug Absorption: Gastric Emptying and Gastrointestinal Motility", <i>Pharmacokinetics</i> , Chapter 6, 267-284, <b>Plaintiff's Exhibit 131</b>	
	<b>94</b>	Patent Data, <b>Plaintiff's Exhibit 143</b> , 1 page	
	<b>95</b>	Product Monograph, "Once-a-Day Ditropan® XL, <b>Plaintiff's Exhibits 157</b> , DXL-044976 thru DXL-045027	
	<b>96</b>	Anderson, R.U. et al., "Once Daily Controlled Versus Immediate Release Oxybutynin Chloride for Urge Urinary Incontinence", <i>The Journal of Urology</i> , June 1999, 161, 1809-1812, <b>Plaintiff's Exhibit 197</b>	
	<b>97</b>	Versi, E. MD, PhD. Et al., "Dry Mouth with Conventional and Controlled Release Oxybutynin in Urinary Incontinence", <i>Obstetrics &amp; Gynecology</i> , 2000, 95(5), 718-721, <b>Plaintiff's Exhibit 198</b>	
	<b>98</b>	Appell, R.A. MD. et al., "Prospective Randomized Controlled Trial of Extended-Release Oxybutynin Chloride and Tolterodine Tartrate in the Treatment of Overactive Bladder: Results of the OBJECT Study", <i>May Clin. Proc.</i> , 2001, 76, 358-363, <b>Plaintiff's Exhibit 199</b>	
	<b>99</b>	OROS TDC-1 Meeting Minutes, November 23, 1993, DXL-027199-02713, <b>Plaintiff's Exhibit 203</b>	
	<b>100</b>	Cystrin Cr-Release Rate Profile, August 14, 1998, DXL-017224-017225, <b>Plaintiff's Exhibit 213</b>	
<b>16</b>	<b>101</b>	Patent Data-DXL 016934, <b>Plaintiff's Exhibit 260</b>	
EXAMINER <b>16</b>		DATE CONSIDERED <b>7-6-06</b>	

<b>Form PTO-1449 Modified</b>  <b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>		<b>Docket No.</b> <b>ALZA-0143</b>	<b>Application No.</b> <b>10/645,715</b>
		<b>Applicant</b> <b>George V. Guittard, et al.</b>	
		<b>Filing Date</b> <b>August 20, 2003</b>	<b>Group</b> <b>1614</b>
		<b>Confirmation No.</b> <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
KG	102	Gupta, S.K. PhD. et al., "Pharmacokinetics of an Oral Once-a-Day Controlled-Release Oxybutynin Formulation Compared with Immediate-Release Oxybutynin", <i>J. Clin. Pharmacol.</i> , 1999, 39, 289-296, DXL-023945-023952, <b>Plaintiff's Exhibit 261</b>	
	103	Patent Data, MYLAN 1008193-1008196, <b>Plaintiff's Exhibit 266</b>	
	104	Highlights of OROS TDC-1 Meeting, June 28, 1993, DXL 017162, <b>Plaintiff's Exhibit 287</b>	
	105	OROS TDC-1 Meeting Minutes-September 17, 1993, DXL 027224-027236, <b>Plaintiff's Exhibit 288</b>	
	106	Work Plan and Cost Estimate for Stage 2 Activities for OROS® Oxybutynlin, DXL 043711-043715, <b>Plaintiff's Exhibit 289</b>	
	107	Commercial Assessment OROS/TTS TDC-1 Oxybutynin, Stage 3, September 1995, DXL 063416-063563, <b>Plaintiff's Exhibit 308</b>	
	108	OROS TDC-1 Meeting Minutes, October 21, 1993, DXL 027214-027215, <b>Plaintiff's Exhibit 309</b>	
	109	Sathyan, G. et al., "Effect of OROS® Controlled-Release Delivery on the Pharmacokinetics and Pharmacodynamics of Oxybutynin Chloride", <i>J. Clin. Pharmacol.</i> , 2001, 52, 409-417, DXL 051995-052003, <b>Plaintiff's Exhibit 315</b>	
	110	Buyse, G. et al., "Intravesical Pxybutynin for Neurogenic Bladder Dysfunction: Less Systemic Side Effects Due to Reduced First Pass Metabolism", <i>The Journal of Urology</i> , 1998, 160, 892-896, <b>Plaintiff's Exhibit 323</b>	
KG	111	Diokno, A.C. et al., "Prospective, Randomized, Double-blind Study of the Efficacy and Tolerability of the Extended-Release Formulations of Oxybutynin and Tolterodine for Overactive Bladder: Results of the OPERA Trail", <i>Mayo Clin Proc.</i> , 2003, 78, 687-695, <b>Plaintiff Exhibit 326</b>	
<b>EXAMINER</b> KG		<b>DATE CONSIDERED</b> 4/6/06	

<b>Form PTO-1449 Modified</b>  <b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)  <b>U.S. Department of Commerce Patent and Trademark Office</b>	<b>Docket No.</b> <b>ALZA-0143</b>		<b>Application No.</b> <b>10/645,715</b>
	<b>Applicant</b> <b>George V. Guittard, et al.</b>		
	<b>Filing Date</b> <b>August 20, 2003</b>	<b>Group</b> <b>1614</b>	
	<b>Confirmation No.</b> <b>8447</b>		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
KG	112	Gupta, P. K. et al., "Oral Controlled-Release Delivery", <i>Treatise on Controlled Drug Delivery</i> , 1992, PX329_0002-329_0058, <b>Plaintiff's Exhibit 329</b>	
	113	Dmochowski, R.R. et al., "Advancements in Pharmacologic Management of the Overactive Bladder", <i>Urology</i> , 2000, 54(6A), 41-49, <b>Plaintiff's Exhibit 391</b>	
	114	Read, N.W. et al., "Gastrointestinal Dynamics and Pharmacology for the Optimum Design of Controlled-Release Oral Dosage Forms", <i>CRC Critical Reviews in Therapeutic Drug Carrier Systems</i> , 1987, 4(3), 221-263, <b>Plaintiff's Exhibits 397</b>	
	115	Miyamoto, E. et al., "Physico-Chemical Properties of Oxybutynin", <i>Analyst</i> , 1994, 119, 1489-1492, DXL 005871-005874	
	116	Modern Pharmaceuticals, Oral Drug Delivery, Chapter 5, ALZA Research Library, DXL 043878 thru DXL 043926, <b>Plaintiff's Exhibit 403</b>	
	117	Physicians' Desk Reference®, PDR®, 47 <sup>th</sup> Edition, 1993, 1377-1378, DXL 028121-DXL 028123, <b>Plaintiff's Exhibit 451</b>	
	118	Longer, M.A. et al., "Sustained-Release Drug Delivery Systems", <i>Pharmaceutical Sciences</i> , 1985, 92, 1644-1661, <b>Plaintiff's Exhibit 462</b>	
	119	Patent Data, JJ 00142 thru JJ 00281, <b>Plaintiff's Exhibit 464</b>	
	120	Banker, G.S., "Pharmaceutical Applications of Controlled Release: An Overview of the Past, Present, and Future", <i>Medical Applications of Controlled Release</i> , 1984, Volume II, 1-34, <b>Plaintiff's Exhibit 467</b>	
KG	121	Yu, L.X. et al., "Transport Approaches to the Biopharmaceutical Design of Oral Drug Delivery Systems: Prediction of Intestinal Absorption", <i>Advanced Drug Delivery Reviews</i> , 1996, 19, 359-376, <b>Plaintiff's Exhibit 471</b>	
EXAMINER		KG	DATE CONSIDERED 4/6/06

<b>Form PTO-1449 Modified</b>  <b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Gulttard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>122</b>	<b>122</b>	Lipka, E. et al., "Setting Bioequivalence Requirements fro Drug Development based on Preclinical Data: Optimizing Oral Drug Delivery Systems", <i>Journal of Controlled Release</i> , 1999, 62, 41-49, <b>Plaintiff's Exhibit 473</b>	
	<b>123</b>	Lukkari, E. et al., "Effect of Food on the Bioavailability of Oxybutynin from a Controlled Release Tablet", <i>Eur. J. Clin. Pharmacol.</i> , 1996, 50, 221-223, <b>Plaintiff's Exhibit 482</b>	
	<b>124</b>	Rocca, J. G. PhD. et al., "Oral Drug Delivery: Prospects & Challenges", <i>Drug Delivery Technology</i> , 2004, 4(4), 53-57, <b>Plaintiff's Exhibit 484</b>	
	<b>125</b>	Waldeck, K. et al., "Comparison of Oxybutynin and its Active Metabolite, N-Desethyl-Oxybutynin, in the Human Detrusor and Parotid Gland", <i>The Journal of Urology</i> , 1997, 157, 1093-1097, <b>Plaintiff's Exhibit 486</b>	
	<b>126</b>	Chancellor, M.B. Md, et al., "A Comparison of the Effects on Saliva Output of Oxybutynin Chloride and Tolterodine Tartrate", <i>Clinical Therapeutics</i> , 2001, 23(5), 753-760, <b>Plaintiff's Exhibit 488</b>	
	<b>127</b>	Laboratory Notebook, Biomaterials & Drug Delivery Labs, <b>Plaintiff's Exhibit 491</b>	
	<b>128</b>	Patent Data- <b>Plaintiff's Exhibit 494 (d)</b>	
	<b>129</b>	Patent Data- <b>Plaintiff's Exhibit 495 (e)</b>	
	<b>130</b>	Patent Data- <b>Plaintiff's Exhibit 496 (f)</b>	
	<b>131</b>	Patent Data- <b>Plaintiff's Exhibit 497 (g)</b>	
EXAMINER <b>KG</b>		DATE CONSIDERED <b>4/06</b>	

<b>Form PTO-1449 Modified</b>  <b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)  <b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Docket No.</b> <b>ALZA-0143</b>	<b>Application No.</b> <b>10/645,715</b>
		<b>Applicant</b> <b>George V. Guittard, et al.</b>	
		<b>Filing Date</b> <b>August 20, 2003</b>	<b>Group</b> <b>1614</b>
		<b>Confirmation No.</b> <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
KG	132	Alza Corporation v. Mylan Laboratories, Inc. and Mylan Pharmaceuticals, Inc, No: 1:03cv61-Supplemental Expert Report of Anthony Lowman, Lowman Video, <b>Plaintiff's Exhibit 498 (h)</b> , 1 page copy of the disc only	
	133	Stage 0: Product Concept Assessment Form Synopsis, March 2, 1993, DXL- 016939 thru 016948, <b>Plaintiff's Exhibit 503</b>	
	134	Translation of Finnish Package Insert (from Swedish language), DXL 012241-012243, <b>Plaintiff's Exhibit 506</b>	
	135	Patent Data- JJ 02815 thru JJ 02817, <b>Plaintiff's Exhibit 536, 538</b>	
	136	Patent Data- <b>Plaintiff's Exhibit 548, 549, 550, 551</b>	
	137	Curriculum Vitae of Nicholas A. Peppas, 1- 113, <b>Plaintiff's Exhibit 552,</b>	
	138	General Information- In Vitro and In Vivo Evaluation, <i>The United States Pharmacopeia Convention, Inc.</i> , 2161, <b>Plaintiff's Exhibit 554</b>	
	139	Patent Data-Drug Release Profile- <b>Plaintiff's Exhibit 555</b> , MYLAN 1014477-1014492	
	140	Curriculum Vitae of Anthony M. Lowman, Ph.D., 15 pages, <b>Plaintiff's Exhibit 556</b>	
KG	141	Chancellor, M.B. et al., "Spit Study to Compare Different Formulations of Oxybutynin", Accepted as Poster Presentation at 1999 AUA, <b>Plaintiff's Exhibit 561</b> , DXL 048067, <b>Plaintiff's Exhibit 561</b>	
<b>EXAMINER</b> KG		<b>DATE CONSIDERED</b> 4/06	

Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
	Applicant <b>George V. Guittard, et al.</b>	
	Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
	Confirmation No. <b>8447</b>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
146	142	Gittleman, M. et al., "Once-Daily Oxybutynin Chloride (Ditropan XL) in Patients on other Anticholinergic Medications", Accepted as Poster Presentation at 1999 AUA, <b>Plaintiff's Exhibit 562, DXL 048068</b>
	143	Sand, P. Md. et al., "Dose Titration with Once-Daily Oxybutynin Chloride (Ditropan XL) in Previously Treated and Naïve Patients", Accepted as Oral Presentation at 1999 ACOG, <b>Plaintiff's Exhibit 563, DXL 048071</b>
	144	Versi, E. Md. et al., "Improving Urge Incontinence Treatments by Decreasing Dry Mouth with Controlled-Release Oxybutynin (Ditropan XL), Accepted as Poster Presentation at 1999 ACOG, <b>Plaintiff's Exhibit 566, DXL 048072</b>
	145	Schmidt, R.A., "Efficacy of Controlled-Release Once-a-Day Oxybutynin Chloride for Urge Urinary Incontinence", <i>Division of Urology</i> , <b>Plaintiff's Exhibit 567, DXL 048073</b>
	146	Brown, J., "Comparison of tolerability and Efficacy of Once-a-Day vs. Immediate-Release Oxybutynin Chloride in Patients with Urge Urinary Incontinence", 1998, <b>Plaintiff's Exhibit 569, DXL 048078</b>
	147	Michel, M.C., "A Benefit-Risk Assessment of Extended-Release Oxybutynin" <i>Drug Safety</i> , 2002, 25(12), 867-876, <b>Plaintiff's Exhibit 570</b>
	148	Physicians' Desk Reference®, 1994, 48 edition, 20, <b>Plaintiff's Exhibit 577</b>
	149	Oxybutynin Chloride Extended Release Tablets 10 mg, Finished Product Specifications, MYLAN 0046025-0046026, <b>Plaintiff's Exhibit 579</b>
	150	Patent Data-MYLAN 1006248-1006257, <b>Plaintiff's Exhibit 591</b>
146	151	Patent Data- <b>Plaintiff's Exhibit 592, 593, 594, 595</b>
EXAMINER 146	DATE CONSIDERED 4/06	

<b>Form PTO-1449 Modified</b>  <b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>		<b>Docket No.</b> <b>ALZA-0143</b>	<b>Application No.</b> <b>10/645,715</b>
		<b>Applicant</b> <b>George V. Guittard, et al.</b>	
		<b>Filing Date</b> <b>August 20, 2003</b>	<b>Group</b> <b>1614</b>
		<b>Confirmation No.</b> <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
166	152	<b>Patent Data-Experimental Formula Sheet- MYLAN 1014435-1014466, Plaintiff's Exhibit 596</b>	
	153	<b>Qureshi, S.A. et al., "Typical Variability in Drug Dissolution Testing: Study with USP and FDA Calibrator Tablets and a Marketed Drug (Glibenclamide) Product", <i>European Journal of Pharmaceutical Sciences</i>, 1999, 7, 249-258, Plaintiff's Exhibits 598</b>	
	154	<b>Patent Data- Plaintiff's Exhibit 602 thru 649</b>	
	155	<b>Curriculum Vitae- Michael B. Chancellor, M.D., 83 pages, Plaintiff's Exhibit 650</b>	
	156	<b>Goldenberg, M.M. PhD. "An Extended Release Formulation of Oxybutynin Chloride for the Treatment of Overactive Urinary Bladder", <i>Clinical Therapeutics</i>, 1999, 21(4), 634-642, DXL 052302-052031, Defendant's Exhibit 656</b>	
	157	<b>Ouslander, J.G. MD., "Management of Overactive Bladder", <i>The New England Journal of Medicine</i>, 2004, 350, 786-799, Plaintiff's Exhibit 664</b>	
	159	<b>Abrahamsson, B. et al., "Absorption, Gastrointestinal Transit, and Tablet Erosion of Felodipine Extended-Release (ER) Tablets", <i>Pharmaceutical research</i>, 1993, 10(5), 709-714</b>	
	160	<b>Artursson, P., "Epithelial Transport of Drugs in Cell Culture. I: A Model for Studying the Passive Diffusion of Drugs over Intestinal Absorptive (Caco-2) Cells", <i>Journal of Pharmaceutical Sciences</i>, June 1990, 79(6), 476-482</b>	
166	161	<b>Chao, S.T. et al., "Effect of Food on Bioavailability of Pseudoephedrine and Brompheniramine Administered from a Gastrointestinal Therapeutic System", <i>Journal of Pharmaceutical Sciences</i>, 1991, 80(5), 432-435</b>	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b> 4/66	

<b>Form PTO-1449 Modified</b>  <b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)  <b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Docket No.</b> <b>ALZA-0143</b>	<b>Application No.</b> <b>10/645,715</b>
		<b>Applicant</b> <b>George V. Guittard, et al.</b>	
		<b>Filing Date</b> <b>August 20, 2003</b>	<b>Group</b> <b>1614</b>
		<b>Confirmation No.</b> <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
KG	162	Chung, M. PhD. et al. "Clinical Pharmacokinetics of Nifedipine Gastrointestinal Therapeutic System", <i>The American Journal of Medicine</i> , 1987, 83, 10-14	
	163	Davis, S.S. et al., "Relationship between the rate of Appearance of Oxprenolol in the Systemic Circulation and the Location of an Oxprenolol Oros 16/260 Drug Delivery System within the Gastrointestinal Tract as Determined by Scintigraphy", <i>Br. J. Clin. Pharmac.</i> , 1988, 26, 435-443	
	164	Harder, S. et al., "Ciprofloxacin Absorption in Different Regions of the Human Gastrointestinal Tract. Investigations with the hf-Capsule", <i>Br. J. Clin. Pharmac.</i> , 1990, 30, 35-39	
	165	Hirtz, J., "The Absorption Window; Fact or Fiction?", <i>Pharmacy International</i> , 1984, 175-178	
	166	Marathe, P.H. et al., "Absorption and Presystemic Metabolism of Nefazodone Administered at Different Regions in the Gastrointestinal Tract of Humans", <i>Pharmaceutical Research</i> , 1995, 12(11), 1716-1721	
	167	Riley, S.A. et al., "Absorption of Polar Drugs following Caecal Instillation in Healthy Volunteers", <i>Aliment Pharmacol Ther.</i> , 1992, 6, 701-706	
	168	Sandberg, A. et al., "Steady-State Bioavailability and Day-to-Day Variability of a Multiple-Unit (CR/ZOK) and a Single-Unit (OROS) delivery System of Metoprolol after Once-Daily Dosing", <i>Pharmaceutical Research</i> , 1993, 10(1), 28-34	
	169	Stiehl, A. et al., "Colonic Absorption of Ursodeoxycholic Acid in Man", 42, 323-325	
	170	Wilding, I.R. et al., "Gastrointestinal Transit and Systemic Absorption of Captopril from a Pulsed-Release Formulation", <i>Pharmaceutical Research</i> , 1992, 9(5), 654-657	
KG	171	Williams, M.F. et al., "Influence of Gastrointestinal Site of Drug Delivery on the Absorption Characteristics of Ranitidine", <i>Pharmaceutical Research</i> , 1992, 9(9), 1190-1194	
EXAMINER KG		DATE CONSIDERED KG	

<b>Form PTO-1449 Modified</b>  <b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>		<b>Docket No.</b> <b>ALZA-0143</b>	<b>Application No.</b> <b>10/645,715</b>
		<b>Applicant</b> <b>George V. Guittard, et al.</b>	
		<b>Filing Date</b> <b>August 20, 2003</b>	<b>Group</b> <b>1614</b>
		<b>Confirmation No.</b> <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
KG	172	Wilson, C.G. et al., "Bimodal release of Ibuprofen in a Sustained-Release Formulation: A Scintigraphic and Pharmacokinetic Open Study in Healthy Volunteers under Different Conditions of Food Intake", <i>International Journal of Pharmaceutics</i> , 1989, 50, 155-161	
	173	Antonin, K-H., "Other Methods in Studying Colonic Drug Absorption", Chapter 5, 89-107	
	174	Antonin, K.H. et al., "Evaluation of the Colonic Drug Absorption in Patients with an Artificial Intestinal Stoma and by Colonoscopy in Normal Volunteers", <i>National Library of Medicine</i> , 39-52	
	175	Bieck, P.R., "Drug Absorption from the Human Colon", <i>Acta Pharm Technol</i> , 1987, 33, 109-114	
	176	Davis, S.S., "Assessment of Gastrointestinal Transit and Drug Absorption", <i>Drug Delivery and its Therapeutic Application</i> , 1989, 9, 89-101	
	177	Hirtz, J., "Intubation Techniques for the Study of the Absorption of Drugs in Man", <i>National Library of Medicine</i> , 3-12	
	178	Hirtz, J., "The Gastrointestinal Absorption of Drugs in Man: A Review of Current Concepts and Methods of Investigation", <i>Br. J. Clin. Pharmac</i> , 1985, 19, 77S-83S	
	179	Schuster, O. et al., "Course of Development of the HF-Capsule-Variations and Method-Related Typical Findings", <i>National Library of Medicine</i> , 28-38	
	180	Colonic Absorption Review Articles, <b>Defendant's Exhibit DX 2003</b> , 1 page	
KG	181	Fara, J.W., "Colonic Drug Absorption and Metabolism", <i>Novel Drug Delivery and its Therapeutic Application</i> , 1989, 10, 103-112, <b>Defendant's Exhibit DX 2004</b>	
EXAMINER		KG	DATE CONSIDERED 4/06

<b>Form PTO-1449 Modified</b>  <b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)  <b>U.S. Department of Commerce Patent and Trademark Office</b>	<b>Docket No.</b> <b>ALZA-0143</b>		<b>Application No.</b> <b>10/645,715</b>
	<b>Applicant</b> <b>George V. Guittard, et al.</b>		
	<b>Filing Date</b> <b>August 20, 2003</b>	<b>Group</b> <b>1614</b>	
	<b>Confirmation No.</b> <b>8447</b>		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
KG	182	Summary of Dr. Dmochowski's ALZA Contracts, <b>Defendant's Exhibit DX 2005</b>	
	183	Summary of Dr. Chancellor Contracts, <b>Defendant's Exhibit DX 2006</b>	
	184	Alza Total Payments to Dr. Chancellor, <b>Defendant's Exhibit DX 2007 and DX 2007 A</b>	
	185	Articles Regarding First-Pass Metabolisms, <b>Defendant's Exhibit DX 2008, 1 page</b>	
	186	Articles Regarding Reduced Side Effects from Non-Oral Administration, <b>Defendant's Exhibit DX 2009, 1 page</b>	
	187	Aaltonen, L. et al., "Antimuscarinic Activity of Oxybutynin in the Human Plasma Quantitated by a Radioreceptor Assay", <i>Acta Pharmacol. Et Toxicol</i> , 1984, 55, 100-103	
	188	Hughes, K.M. et al., "Measurement of Oxybutynin and its N-Desethyl Metabolite in Plasma and its Application to Pharmacokinetic Studies in Young, Elderly and Frail Elderly Volunteers", <i>Xenobiotica</i> , 1992, 22(7), 859-869	
	189	Abstracts of the 1 <sup>st</sup> Congress of the European Association for Clinical Pharmacology and Therapeutics, 1995, <i>Thérapie</i> , 65-68, <b>Plaintiff's Exhibit 485</b>	
	190	Madersbacher, H. Md. et al., "Control of Detrusor Hyperreflexia by the Intravesical Instillation of Oxybutynine Hydrochloride", <i>Paraplegia</i> , 1991, 29, 84-90	
KG	191	Ditropian XI, Prescribing Information, <b>Joint Exhibit 239, 2 pages</b>	
EXAMINER		KG	DATE CONSIDERED 4/06

<b>Form PTO-1449 Modified</b>  <b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)  <b>U.S. Department of Commerce Patent and Trademark Office</b>	<b>Docket No.</b> <b>ALZA-0143</b>	<b>Application No.</b> <b>10/645,715</b>
	<b>Applicant</b> <b>George V. Guittard, et al.</b>	
	<b>Filing Date</b> <b>August 20, 2003</b>	<b>Group</b> <b>1614</b>
	<b>Confirmation No.</b> <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
KG	<b>192</b>	<b>OROS Oxybutynin Release Rates Patent Data-Joint Exhibit 27</b>
	<b>193</b>	<b>OROS Oxybutynin Release Rates Patent Data-Joint Exhibit 28</b>
	<b>194</b>	<b>OROS Oxybutynin Release Rates Patent Data Patent Data-Joint Exhibit 29</b>
	<b>195</b>	<b>OROS Oxybutynin Release Rates Patent Data Patent Data-Joint Exhibit 30</b>
	<b>196</b>	<b>OROS Oxybutynin Release Rates Patent Data Patent Data-Joint Exhibit 31</b>
	<b>197</b>	<b>OROS Oxybutynin Release Rates Patent Data Patent Data-Joint Exhibit 32</b>
	<b>198</b>	<b>OROS Oxybutynin Release Rates Patent Data Patent Data-Joint Exhibit 33</b>
	<b>199</b>	<b>OROS Oxybutynin Release Rates Patent Data Patent Data-Joint Exhibit 35</b>
	<b>200</b>	<b>Appendix D-List of Documents Reviewed-Joint Exhibit 47</b>
KG	<b>201</b>	<b>Alza Corp. v. Mylan, C.A. # 1:03CV61, Expert Report of Dr. Gordon Amidon, Appendix J: Photo of Different Dosage Forms CD, Joint Exhibit 53</b>
<b>EXAMINER</b>	KG <b>DATE CONSIDERED</b> 4/06	

<b>Form PTO-1449 Modified</b>  <b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>K6</b>	<b>202</b>	Lish, P.M., "Oxybutynin-A Musculotropic Antispasmodic Drug with Moderate Anticholinergic Action", <i>Mead Johnson Research Center</i> , 1964, 467-488, DXL 014384-014406, <b>Joint Exhibit 54</b>	
	<b>203</b>	Experimental Formula Sheet Patent Data- MYLAN 1014326-1014370, <b>Joint Exhibit 55</b>	
	<b>204</b>	Declaration of Dr. William Barr, <b>Joint Exhibit 56</b> , 7 pages	
	<b>205</b>	Declaration of Dr. Patrick S.L. Wong, <b>Joint Exhibit 57</b> , 14 pages	
	<b>206</b>	Draft Annotated Physician Insert-DITROPAN® XL, DXL 072395-DXL 072407, <b>Joint Exhibit 78</b>	
	<b>207</b>	Rovner, E.S., et al., "Once-Daily, Extended-Release Formulations of Antimuscarinic Agents in the Treatment of Overactive Bladder: A Review", <i>European Urology</i> , 2002, 41, 6-14, <b>Joint Exhibit 84</b>	
	<b>208</b>	Guidance for Industry, Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In/Vitro/In Vivo Correlations, <i>U.S. Dept. of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research</i> , September 1997, 1-24, <b>Joint Exhibit 86</b>	
	<b>209</b>	Pitsiu, M. et al., "A Semiparametric Deconvolution Model to Establish in Vivo-In Vitro Correlation Applied to OROS Oxybutynin", <i>Journal of Pharmaceutical Sciences</i> , 2001, 90(6), 702-712, <b>Joint Exhibit 89</b>	
	<b>210</b>	Barr Affidavit, 1-23, <b>Joint Exhibit 90</b>	
<b>K6</b>	<b>211</b>	Letter from S. Wayne Talton to Gary J. Buehler, re: Oxybutynin Chloride Extended-Release Tablets, 10mg and 76-644 Response to Agency Correspondence dated December 8, 2003, MYLAN 0978814-097835 w attached patent data, <b>Joint Exhibit 91</b>	
EXAMINER <b>K6</b>		DATE CONSIDERED <b>4/06</b>	

<b>Form PTO-1449 Modified</b>  <b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Docket No.</b> <b>ALZA-0143</b>	<b>Application No.</b> <b>10/645,715</b>
	<b>Applicant</b> <b>George V. Guittard, et al.</b>	
	<b>Filing Date</b> <b>August 20, 2003</b>	<b>Group</b> <b>1614</b>
	<b>Confirmation No.</b> <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
166	<b>212</b>	Theeuwes, F., "Evolution and Design of Rate Controlled Osmotic Forms", <i>Current Medical Research and Opinion</i> , 1983, 8(2), 20-27, <b>Joint Exhibit 93</b>
	<b>213</b>	Theeuwes, F., et al. "Systems for Triggered, Pulsed, and Programmed Drug Delivery", <i>Annals New York Academy of Science</i> , 428-440, <b>Joint Exhibit 94</b>
	<b>214</b>	Peters, K.M. et al., "Urinary Incontinence", 685-688, <b>Joint Exhibit 95</b>
	<b>215</b>	Yarker, Y.E. et al., "Oxybutynin-A review of its Pharmacodynamic and Pharmacokinetic Properties, and its Therapeutic Use in Detrusor Instability", <i>Drug and Aging</i> , 1993, 3, 243-262, <b>Joint Exhibit 96</b>
	<b>215A</b>	Hughes, K.M. et al., "Measurement of Oxybutynin and its N-Desethyl Metabolite in Plasma, and its Application to Pharmacokinetic Studies in Young, Elderly and Frail Elderly Volunteers", <i>Xenobiotica</i> , 1992, 22(7), 859-869, <b>Joint Exhibit 97</b>
	<b>216</b>	Robinson, T.G. et al., "Drugs in Focus: Oxybutynin Hydrochloride", <i>Prescribers' Journal</i> , 1994, 34(1), 27-31, <b>Joint Exhibit 98</b>
	<b>217</b>	Katori, N. et al., "Estimation of Agitation Intensity in the GI Tract in Humans and Dogs Based on <i>in Vitro/in Vivo</i> Correlation", <i>Pharmaceutical Research</i> , 1995, 12(2), 237-243, <b>Joint Exhibit 99</b>
	<b>218</b>	Lukkari, E. et al., "Effect of Time Interval between Food and Drug Ingestion on the Absorption of Oxybutynin from a Controlled-Release Tablet", <i>Pharmacology &amp; Toxicology</i> , 1997, 81, 31-34, DXL 005964-005967 <b>Joint Exhibit 101</b>
	<b>219</b>	Declaration of Dr. Patrick S.L. Wong, <b>Joint Exhibit 107</b> , 28 pages
	<b>220</b>	Declaration of Dr. William Barr, <b>Joint Exhibit 108</b>
166	<b>221</b>	Patent Data-Ditropan XL 2003 OE/2004BP/2005 Forecast, JJ 00497-00577, <b>Plaintiff's Exhibit 139</b>
<b>EXAMINER</b>	168	<b>DATE CONSIDERED</b> 4/06

<b>Form PTO-1449 Modified</b>  <b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Docket No.</b> <b>ALZA-0143</b>	<b>Application No.</b> <b>10/645,715</b>
	<b>Applicant</b> <b>George V. Guittard, et al.</b>	
	<b>Filing Date</b> <b>August 20, 2003</b>	<b>Group</b> <b>1614</b>
	<b>Confirmation No.</b> <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
K6	222	Collas, D. et al., "The Pharmacokinetic Properties of Rectal Oxybutynin- a Possible Alternative to Intravesical Administration", <i>Neurourology and Urodynamics</i> , 1997, 16(5), 346-347
	223	Madersbacher, M. et al., "Intravesical Application of Oxybutynine: Mode of Action in Controlling Detrusor-Hyperreflexia", <i>Dept. Urology, Univ. Hosp. Innsbruck and Rehab Center</i> , 375-376
	224	Mizunaga, M, Md. et al., "Intravesical Instillation of Oxybutynin Hydrochloride Therapy for Patients with a Neuropathic Bladder", <i>Paraplegia</i> , 1994, 32, 25-29
	225	Weese, D.L. et al., "Intravesical Oxybutynin Chloride: Experience with 42 Patients", <i>Urology</i> , June 1993, 41(6), 527-530
	226	O'Flynn, K.J. et al., "Intravesical Instillation of Oxybutynin Hydrochloride for Detrusor Hyper-Reflexia", <i>British Journal of Urology</i> , 1993, 72, 566-570
	227	Remington's Pharmaceutical Sciences, "Pharmacokinetic Models", 36, 726
	228	Lukkari, E., "Clinical Pharmacology of Oxybutynin, with Special Reference to Pharmacokinetics and Interactions", <i>Department of Clinical Pharmacology</i> , 1997, 1-50, PW 000281-000331
	229	Nilsson, C.G. et al. "Comparison of a 10-mg Controlled Release Oxybutynin Tablet with a 5-mg Oxybutynin Tablet in Urge Incontinent Patients", <i>Neurourology and Urodynamics</i> , 1997, 16, 533-542, DXL 012130-012139
	230	"Cystrin CR Launched in Finland for Urinary Incontinence", <i>Doctor's Guide to Medical &amp; Other News</i> , <a href="http://www.pslgroup.com">http://www.pslgroup.com</a> , May 7, 1998, 2 pages
K6	231	Fincher, J.H., "Particle Size of Drugs and its relationship to Absorption and Activity", <i>J. Pharm. Sci.</i> , 1968, 57, 1825-1835
<b>EXAMINER</b> K6	<b>DATE CONSIDERED</b> 4/06	

<b>Form PTO-1449 Modified</b>  <b>List of Patent and Publications Cited by Applicant</b> (Use several sheets if necessary)  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>		<b>Docket No.</b> <b>ALZA-0143</b>	<b>Application No.</b> <b>10/645,715</b>
		<b>Applicant</b> <b>George V. Guittard, et al.</b>	
		<b>Filing Date</b> <b>August 20, 2003</b>	<b>Group</b> <b>1614</b>
		<b>Confirmation No.</b> <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
KG	232	King, R.E. PhD. et al., "Oral Solid Dosage Forms", <i>Pharm. Sci. by Remington</i> , 17 <sup>th</sup> Ed., Ch. 90, pp. 1603-1625 (1985), published by Mack Publishing	
	233	Linhardt, R.J., "Biodegradable Polymers for Controlled Release of Drugs", Edited by M. Rosoff, Ch 2, pp. 53-95 (1989)	
	233A	Riva, D. et al., "Oxybutynin Chloride in the Treatment of female Idiopathic ladder Instability, <i>Clin. Exp. Obst. Gyn</i> , 1984, 37-42	
	234	Coleman, M.M et al., "A Practical Guide to Polymer Miscibilit", <i>Polymers</i> , 31, 1187-1231 (1990)	
	235	Drug Carrier Systems, by Roerdink et al., vol. 9, pp. 57-109 (1989)	
	236	Leong, K.W. et al., "Polymeric Controlled Drug Delivery", <i>Advanced Drug Delivery Reviews</i> , vol 1, 199-233 (1987)	
	237	Handbook of Common Polymers, Compiled by Roff et al., (1971), published by CRC Press, 72-81	
	238	Wurster, D.E., "Air-Suspension Technique of Coating Drug Particles," <i>Journal of the American Pharmaceutical Association</i> , 48, 451-454 (Aug. 1959)	
	239	Wurster, D.E., "Preparation of Compressed Tablet Granulations by the Air-Suspension Technique II," <i>Journal of the American Pharmaceutical Association</i> , 49, 82-84 (Feb.1960)	
	240	Pharmaceutical Sciences by Remington, 14 <sup>th</sup> Ed., pp. 1626-1680 (1970), published by Mack Publishing Co.	
KG	241	Database WPI, Derwent Publication Ltd., London, GB, AN 94-031722, XP002096607	
EXAMINER		KG	DATE CONSIDERED 4/06

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
66	242	Database WPI, Derwent Publication Ltd., London, GB, AN 94-068306, XP002096606	
	243	Gupta, S.K. et al., "Evidence for Site-Specific Presystemic Metabolism of Oxybutynin Following Oral Administration," <i>Clinical Pharmacology &amp; Therapeutics</i> , 61, 2, 1997, p. 227, XP002099744	
	244	In the United States District Court for the Northern District of California, Alza Corporation, Plaintiff v. Impax Laboratories, Defendant, Case No. C-03-4032-VRW and C-03-4795, Decision Not to Dismiss California Declaratory Judgment Action, <b>No Date</b>	
	245	IMPAX Notice of Paragraph IV Certification Letter regarding IMPAX Oxybutynin Chloride, 15 mg. Tablets w/Appendix, <b>July 25, 2003</b>	
	246	IMPAX Notice of Paragraph IV Certification Letter regarding IMPAX Oxybutynin Chloride, 5 and 10 mg. Tablets w/Appendix, <b>August 19, 2003</b>	
	247	In the United States District Court for the Northern District of California, Oakland Division, Case No. C-03-04032, Complaint for Patent Infringement w/Exhibit A, <b>September 4, 2003</b>	
	248	In the United States District Court for the Northern District of California, Oakland Division, Case No. C-03-04032, Answer, Affirmative Defenses and Counterclaims of IMPAX Laboratories, Inc., <b>October 1, 2003</b>	
	249	In the United States District Court for the Northern District of California, San Francisco Division, Case No. C-03-04032, Plaintiff ALZA Corporation's Reply to Defendant IMPAX Laboratories, Inc.'s Counterclaims, <b>November 13, 2003</b>	
	250	In the United States District Court for the Northern District of California, San Francisco Division, Case No. C-03-04032, IMPAX'S Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-8), <b>May 20, 2004</b>	
	251	In the United States District Court for the Northern District of California, Case No. C-03-4032 VRW, Order, <b>No Date</b>	
66	252	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Plaintiff ALZA Corporation's Opening Memorandum of Law in Support of Claim Constructions, <b>December 15, 2004</b>	
EXAMINER 66		DATE CONSIDERED 4/06	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
KG	253	In the United States District Court for the Northern District of California, San Francisco Division, Case No. C-03-04032, IMPAX'S Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-8), <b>May 20, 2004</b>	
	254	In the United States District Court for the Northern District of California, Case No. C-03-4032 VRW, Order, <b>No Date</b>	
	255	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Plaintiff ALZA Corporation's Opening Memorandum of Law in Support of Claim Constructions, <b>December 15, 2004</b>	
	256	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Declaration of Nicholas A. Peppas in Support of Plaintiff ALZA Corporation's Opening Memorandum of Law in Support of Claim Construction w/Exhibit A, <b>December 15, 2004</b>	
	257	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Declaration of David Eiseman in Support of Plaintiff ALZA Corporation's Opening Memorandum of Law in Support of Claim Construction w/Exhibits A-F, <b>December 15, 2004</b>	
	258	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Plaintiff ALZA Corporation's Objections and Responses to IMPAX Laboratories, Inc.'s First Set of Interrogatories, <b>January 10, 2005</b>	
	259	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Plaintiff ALZA Corporation's Supplemental Opening Memorandum of Law in Support of Claim Construction w/Exhibits A-J, <b>January 13, 2005</b>	
	260	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Defendant IMPAX Laboratories Inc.'s Responsive Claim Construction Brief, <b>March 10, 2005</b>	
KG	261	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Declaration of Mark I. Koffsky in Support of Defendant IMPAX Laboratories Inc.'s Responsive Claim Construction Brief, w/Exhibits A-B, <b>March 10, 2005</b>	
EXAMINER		KG	DATE CONSIDERED 4/06

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>KG</b>	<b>262</b>	In the United States District Court, Northern District of California, San Francisco Division, Case No. C-03-04032, Declaration of Lewis J. Leeson in Support of Defendant IMPAX Laboratories Inc.'s Responsive Claim Construction Brief, w/Exhibit A, <b>March 10, 2005</b>	
<b>KG</b>	<b>263</b>	IMPAX Notice of Paragraph IV Certification Letter regarding IMPAX Oxybutynin Chloride 5, 10 and 15mg. (and patent validity) Tablets w/Appendix, <b>July 19, 2005</b>	
<b>KG</b>	<b>264</b>	In the United States District Court for the Northern District of West Virginia, ALZA Corporation, Plaintiff, v. Mylan Laboratories, Inc. and Mylan Pharmaceutical, Inc., C.A. # 1:03CV61(Judge Keeley), Post trial Memorandum Opinion and Order, <b>September 27, 2005, 57 pages</b>	
<b>EXAMINER</b>		<b>KG</b>	<b>DATE CONSIDERED</b> <b>4/06</b>

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. <b>ALZA-0143</b>		Application No. <b>10/645,715</b>	
				Applicant <b>George V. Guittard, et al.</b>			
				Filing Date <b>August 20, 2003</b>		Group <b>1614</b>	
				Confirmation No. <b>8447</b>			
<b>U. S. PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
KG	265	4,008,719	02/22/77	Theeuwes, et al.	128	260	
	266	4,783,337	11/08/88	Wong, et al.	424	468	
	267	5,135,757	08/04/92	Baichwal, et al.	434	465	
	268	5,178,868	01/12/93	Malmqvist-Granlund, et al.	424	490	
	269	5,407,686	04/18/95	Patel, et al.	424	468	
	270	5,455,046	10/03/95	Baichwal	424	457	
	271	5,532,278	07/02/96	Aberg, et al.	514	617	
KG	272	6,124,355	09/26/00	Guittard, et al.	514	534	
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Country	Translation		
					YES	NO	
KG	273	AU 47732/90	07/12/90	Australia	X(Abstract)		
KG	274	WO 96/37202	11/28/96	PCT			
<b>EXAMINER</b> KG				<b>DATE CONSIDERED</b> 4/06			

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. <b>ALZA-0143</b>		Application No. <b>10/645,715</b>	
				Applicant <b>George V. Guittard, et al.</b>			
				Filing Date <b>August 20, 2003</b>		Group <b>1614</b>	
				Confirmation No. <b>8447</b>			
<b>U. S. PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
K6	275	4,519,801	05/28/85	Edgren	604	892	
	276	4,612,008	09/16/86	Wong, et al.	604	892	
	277	4,994,276	02/19/91	Baichwal, et al.	424	440	
	278	5,082,668	01/21/92	Wong, et al.	424	473	
	279	5,128,143	07/07/92	Baichwal, et al.	424	464	
	280	5,330,766	07/19/94	Morella, et al.	424	490	
	281	5,399,359	03/21/95	Baichwal .	424	464	
	282	5,498,422	03/12/96	Nakamichi, et al.	424	451	
	283	5,674,895	10/07/97	Guittard, et al.	514	534	
	284	5,811,126	09/22/98	Krishnamurthy	424	498	
	285	5,840,754	11/24/98	Guittard, et al.	514	534	
	286	5,912,268	06/15/99	Guittard, et al.	514	534	
K6	287	6,262,115 B1	07/17/01	Guittard, et al.	514	534	
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Country	Translation		
					YES	NO	
K6	288	WO 96/37202	11/28/96	PCT			
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			
K6				4/06			

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>LG</b>	<b>289</b>	MYLAN Pharmaceuticals Inc. Notice of Paragraph IV Certification Letter regarding <b>IMPAX Oxybutynin Chloride 10 mg. Tablets, March 19, 2003</b>	
	<b>290</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Complaint for Patent Infringement (ALZA) W/Exhibit A, <b>May 2, 2003</b>	
	<b>291</b>	MYLAN Pharmaceuticals Inc. Notice of Paragraph IV Certification Letter regarding <b>IMPAX Oxybutynin Chloride 5 mg. Tablets, May 21, 2003</b>	
	<b>292</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Answer, Defenses and Counterclaims of Defendant Mylan Laboratories Inc., <b>May 27, 2003</b>	
	<b>293</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Reply to MYLAN Pharmaceuticals Inc.'s Counterclaims Filed in Consolidated Action 1:03CV158, <b>July 30, 2003</b>	
	<b>294</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Mylan's Objections and Response to Plaintiff's First Set of Interrogatories, <b>September 18, 2003</b>	
	<b>295</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civ. Action No. 1-03CV61, ALZA's Response to Mylan's First Set of Interrogatories, <b>September 29, 2003</b>	
	<b>296</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civ. Action No. 1-03CV61, ALZA's Response to Mylan's Second Set of Interrogatories, <b>October 8, 2003</b>	
	<b>297</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civ. Action No. 1-03CV61, ALZA's Response to Mylan's Third Set of Interrogatories, <b>December 18, 2003</b>	
<b>Ke</b>	<b>298</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civ. Action No. 1-03CV61, ALZA's Response to Mylan's Fourth Set of Interrogatories, <b>February 17, 2004</b>	
<b>EXAMINER</b>		<b>LG</b>	<b>DATE CONSIDERED</b> <b>4/06</b>

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>166</b>	<b>299</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, ALZA's Response to Mylan's Fifth Set of Interrogatories, <b>March 4, 2004</b>	
	<b>300</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, ALZA's Supplemental Response to Mylan's Fifth Set of Interrogatories (Interrogatory No. 12), <b>March 19, 2004</b>	
	<b>301</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Mylan's Objections and Supplemental Responses to Plaintiff's first Set of Interrogatories, <b>March 21, 2004</b>	
	<b>302</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, ALZA's Second Supplemental Response to Mylan's Fifth Set of Interrogatories (Interrogatory No. 8), <b>March 26, 2004</b>	
	<b>303</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, ALZA's First Supplemental Response to Mylan's Third Set of Interrogatories (No. 6), <b>April 12, 2004</b>	
	<b>304</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Mylan's Pretrial Memorandum, <b>December 2, 2004</b>	
	<b>305</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Order Construing Claims and Denying Summary Judgment, <b>December 7, 2004</b>	
	<b>306</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Plaintiff (ALZA's) Pre-Trial Memorandum (w/Exhibits A-C),	
	<b>307</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civ. Action No. 1-03CV61, Markman Hearing Transcript, <b>December 29, 2004</b>	
<b>166</b>	<b>308</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Mylan's Notice Pursuant to 35 U.S.C. § 282, <b>January 7, 2005</b>	
<b>EXAMINER</b>		<b>166</b>	<b>DATE CONSIDERED</b> <b>4/06</b>

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>K6</b>	<b>309</b>	United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Trial Transcript, <b>April 18, 2005</b>	
	<b>310</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Mylan's Post-Trial Brief, with Exhibits A and B, <b>May 6, 2005</b>	
	<b>311</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Plaintiff (ALZA) Post-Trial Reply Memorandum, <b>June 1, 2005</b>	
	<b>312</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Mylan's Post-Trial Reply Brief, <b>June 1, 2005</b>	
	<b>313</b>	Mylan Letter to Judge Irene M. Keely regarding ALZA's arguments in its Post Trial Reply Brief, 1 page, <b>June 15, 2005</b>	
	<b>314</b>	In the United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Notice of Paragraph IV Certification US Patent 6,919,092 Oxybutynin Chloride Extended Release Tablets, 5 mg. and 10 mg. b, <b>July 22, 2005</b>	
<b>K6</b>	<b>315</b>	In United States District Court for the Northern District of West Virginia Clarksburg Office, Civil Action No. 1-03CV61, Plaintiff (ALZA) Post-Trial Reply Memorandum (Corrected), <b>No Date</b>	
<b>EXAMINER</b>	<b>K6</b>	<b>DATE CONSIDERED</b> <b>4/06</b>	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>K6</b>	<b>316</b>	In the United States District Court for the Northern District of West Virginia, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Supplemental Invalidity Contentions, Mylan's Supplemental Contentions Supporting the Invalidity of U.S. Patent No. 6,124,355, <b>January 29, 2003, 26 pages</b>	
	<b>317</b>	In the United States District Court for the Northern District of West Virginia, at Clarksburg, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Contentions Supporting the Invalidity of U.S. Patent No. 6,124,355, <b>December 29, 2003</b>	
	<b>318</b>	In the United States District Court for the Northern District of West Virginia, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Motion for Summary Judgment(#3) of Invalidity for Indefiniteness Under <i>Honeywell</i> , <b>July 14, 2004, 12 pages</b>	
	<b>319</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Alza's Memorandum in Opposition to Defendant's Motion for Summary Judgment on Invalidity for Indefiniteness Under <i>Honeywell</i> (#3), <b>August 27, 2004, 15 pages</b>	
	<b>320</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Reply Memorandum in Support of its Motion for Summary Judgment (#3) of Invalidity for Indefiniteness Under <i>Honeywell</i> , <b>September 17, 2004, 14 pages</b>	
<b>K6</b>	<b>321</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Reply Memorandum in Support of its Motion for Partial Summary Judgment (#1) on the Threshold "Priority" Issue", With Attached Exhibit A, <b>July 14, 2004</b>	
<b>EXAMINER</b> <b>K6</b>		<b>DATE CONSIDERED</b> <b>4/06</b>	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>KG</b>	<b>322</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Reply Memorandum in Support of Its Motion for Summary Judgment (#2) of Invalidity based on Inherent Anticipation, <b>July 14, 2004</b> , With attached Exhibits A & B	
	<b>323</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Motion for Summary Judgment (#5) of Invalidity Based Upon a Lack of Novelty over the Prior Art, Memorandum in Support of Mylan's Motion for Summary Judgment (#5) of Invalidity Based upon a Lack of Novelty over the Prior Art, <b>July 14, 2004</b>	
	<b>324</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Alza's Memorandum in Opposition to Defendant's Motion for Summary Judgment (#5) of Invalidity based Upon a Supposed Lack of Novelty over the Prior Art, <b>August 27, 2004</b>	
	<b>325</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Reply Memorandum in Support of Its Motion for Summary Judgment (#5) of Invalidity Based Upon a Lack of Novelty over the Prior Art, <b>September 17, 2004</b> , with attached Exhibits A, B	
<b>KG</b>	<b>326</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Plaintiff Alza Corporation's Opening Memorandum of Law in Support of Claim Construction, <b>July 14, 2004</b> , with attached Exhibits A thru I	
<b>EXAMINER</b> <b>KG</b>		<b>DATE CONSIDERED</b> <b>4/06</b>	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>K6</b>	<b>327</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Plaintiff Alza Corporation's Memorandum in Reply to Defendants' Responsive Claim Construction Memorandum, <b>September 3, 2004</b> , with attached Exhibits N thru S	
	<b>328</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Plaintiff Alza Corporation's Response to Defendants' "Markman" Claim Construction Memorandum, <b>August 20, 2004</b> , with attached Exhibits J thru M	
	<b>329</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's "Markman" Reply Memorandum, <b>September 3, 2004</b>	
	<b>329 A</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Reply Memorandum in Support of its Motion for Partial Summary Judgment (#1) on the Threshold "Priority" Issue, <b>September 3, 2004</b>	
	<b>330</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's "Markman" Claim Construction Memorandum, with attached Exhibits A thru C, <b>July 14, 2004</b>	
	<b>331</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Response to Alza's Claim Construction Memorandum, <b>August 20, 2004</b> , with attached Exhibits A, B.	
<b>KB</b>	<b>332</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Motion for Summary Judgment (#2) of Invalidity Based on Inherent Anticipation, <b>July 14, 2004</b>	
<b>EXAMINER</b> <b>K6</b>		<b>DATE CONSIDERED</b> <b>4/06</b>	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>KG</b>	<b>333</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Motion for Partial Summary Judgment (#1) on the Threshold "Priority" Issue, <b>July 14, 2004</b> , w/attached Exhibit A	
	<b>334</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Motion for Summary Judgment (#5) of Invalidity based upon Lack of Novelty over the Prior Art, <b>July 14, 2004</b>	
	<b>335</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Alza's Combined Memorandum in Opposition to Defendant's Motion for Summary Judgment on the Threshold Priority Issue (#1) and Invalidity based on Inherent Anticipation, <b>August 20, 2004</b> , with attached Exhibits A,B	
	<b>336</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Reply Memorandum in Support of Its Motion for Summary Judgment (#2) of Invalidity Based on Inherent Anticipation, <b>September 3, 2004</b>	
	<b>337</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Plaintiff Alza Corporation's Memorandum in Reply to Defendant's Responsive Claim Construction Memorandum, <b>September 7, 2004</b>	
<b>KG</b>	<b>338</b>	In the United States District Court for the Northern District of West Virginia, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Supplemental Briefing on <i>Kennecott</i> and Alleged "Inherent Written Description", <b>November 2, 2004</b>	
<b>EXAMINER</b>		<b>KG</b>	<b>DATE CONSIDERED</b> <b>7/06</b>

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>K6</b>	<b>339</b>	In the United States District Court for the Northern District of West Virginia, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Alza's Memorandum in Response to Mylan's Supplemental Briefing on <i>Kennecott</i> and Alleged "Inherent Written Description", <b>November 13, 2004</b>	
	<b>340</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Plaintiff's Pre-Trial Memorandum, <b>December 22, 2004</b>	
	<b>341</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Memorandum in Support of its Motion for Reconsideration, <b>December 23, 2004</b>	
	<b>342</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Motion for Reconsideration of the Court's Ruling on Summary Judgments # 1 and #2, <b>December 24, 2004</b>	
	<b>343</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Motion for Reconsideration of the Court's Ruling on Summary Judgments #1 and #2, Mylan's Memorandum in Support of its Motion for Reconsideration, <b>January 24, 2005</b>	
<b>K6</b>	<b>344</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Mylan's Reply Memorandum in Support of its Motion for Reconsideration, <b>January 31, 2005</b>	
<b>EXAMINER</b>		<b>K6</b>	<b>DATE CONSIDERED</b> <b>7/06</b>

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>16</b>	<b>346</b>	In the United States District Court for the Northern District of West Virginia, Clarksburg Office, Alza Corporation, Plaintiff, V. Mylan Laboratories, Inc. Mylan Pharmaceuticals, Inc., Civil Action # 1:03CV61, Plaintiff's Post Trial Memorandum(Corrected) <b>June 1, 2005</b>	
	<b>347</b>	Ditropan XL NTS: Projections and Annuals, <b>Defendant's Exhibit DX 2012</b>	
	<b>348</b>	Letter from Michael B. Chancellor, M.D. to Richard McCormick-Re: ALZA v. Mylan [Ditropan XL], <b>Defendant's Exhibit DX 2016</b>	
	<b>349</b>	Quarterly TX Market Share (Updated) , <b>Defendant's Exhibit DX 2017</b>	
	<b>350</b>	Market Share Trends, <b>Defendant's Exhibit DX 2018</b>	
	<b>351</b>	J & J Worldwide Advertising Group media Budget Control Record(MBCR), Ditropan, <b>Defendant's Exhibit DX 2019</b>	
	<b>352</b>	DX 2020-Articles teaching that a Lower Dose of Oxybutynin is Effective and has Fewer Side Effects, <b>Defendant's Exhibit DX 2020</b>	
	<b>353</b>	Ditropan XL: BMEs as a Percent of Net Trade Sales, <b>Defendant's Exhibit DX 2024</b>	
	<b>354</b>	Alza Corporation Physician Advisory Board Meeting, Phoenix, AZ, 1998, <b>Defendants Exhibit DX 2029</b>	
	<b>355</b>	Ditropan-XI TRX Market Share Compared to Rebates (%NTS), <b>Defendants Exhibit DX 2025</b>	
<b>16</b>	<b>356</b>	Chancellor, M.B. MD., "What is Really New in Overactive Bladder?, February 25, 2004, <b>Defendant's Exhibit DX 2038</b>	
<b>EXAMINER</b>		<b>16</b>	<b>DATE CONSIDERED</b> <b>4/06</b>

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>ALZA-0143</b>	Application No. <b>10/645,715</b>
		Applicant <b>George V. Guittard, et al.</b>	
		Filing Date <b>August 20, 2003</b>	Group <b>1614</b>
		Confirmation No. <b>8447</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>K6</b>	<b>357</b>	<b>AWP Price Per Day: TID Oxy Products, Defendant's Exhibit's DX 2039</b>	
	<b>358</b>	<b>Ditropan ® XL, Recommendation for Additional Clinical Study, Defendant's Exhibit 2056,</b>	
	<b>359</b>	<b>Ditropan XL: NTS Compared to Profits, Defendant's Exhibit DX 2061</b>	
	<b>360</b>	<b>Ditropan XL Profits Compared to J &amp; J Investment, Defendant's Exhibit DX 2062</b>	
	<b>361</b>	<b>Ditropan XL Financial Data, Defendant's Exhibits DX 2063</b>	
	<b>362</b>	<b>Ditropan-XL TRX Market Share Compared to BME/Selling (%NTS), Defendant's Exhibits DX 2065</b>	
	<b>363</b>	<b>Ditropan XL ® vs Detrol ® Spit Study, Post-Launch (Stage 5), Defendant's Exhibit DX 2067</b>	
<b>K6</b>	<b>364</b>	<b>Physicians' Desk Reference, PDR®, 42 Edition, 1988, Ditropan Tablets and Syrup</b>	
<b>EXAMINER</b>	<b>K6</b>	<b>DATE CONSIDERED 4/06</b>	